title: Differential prevention of experimental autoimmune encephalomyelitis with antigen-specific DNA vaccination.
abstract: We compared the potential therapeutic effect of vaccination with DNA constructs encoding two encephalitogenic proteins, PLP and MOG, on the outcome of subsequent sensitization of EAE induced in SJL/J and C57/B6 mice. Early sensitization for EAE (4 weeks after DNA vaccination) caused recipient animals to develop enhanced disease with DNA-encoding PLP but not with DNA-encoding MOG. Late sensitization (more than 10 weeks) resulted in an amelioration of EAE in animals vaccinated with both PLP and MOG DNA constructs. These results, confirming the DNA-mediated ameliorating effect on EAE, also indicate significant differences in the kinetics of development of EAE tolerance in response to vaccination with different DNA-encoding myelin antigens. Since PLP and MOG require different MHC presentation and induce different EAE models, the results point to potential differences in immune system requirements for efficient DNA-induced amelioration of the autoimmune response.
authors.affiliation: Department of Neurology, Medical University of Lodz, 22 Kopcinskiego St., 90-153 Lodz, Poland.
authors.forename: Agata
authors.initials: A
authors.lastname: Walczak
authors.forename: Bozena
authors.initials: B
authors.lastname: Szymanska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Selmaj
mesh_terms: D000818:Animals; D001324:Autoantigens / Q000276:immunology*; D019976:Cloning, Organism / Q000379:methods; D017931:DNA Primers / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000378:metabolism / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007114:Immunization / Q000379:methods*; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D007376:Interleukin-2 / Q000096:biosynthesis / Q000276:immunology; D015847:Interleukin-4 / Q000096:biosynthesis / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein / Q000096:biosynthesis / Q000276:immunology*; D018992:Myelin-Associated Glycoprotein / Q000096:biosynthesis / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D010957:Plasmids / Q000008:administration & dosage; D016133:Polymerase Chain Reaction; D012313:RNA / Q000276:immunology; D013997:Time Factors; D019444:Vaccines, DNA / Q000008:administration & dosage*
chemical_list: D001324:Autoantigens; D017931:DNA Primers; D007376:Interleukin-2; C571327:Mog protein, mouse; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D019444:Vaccines, DNA; D015847:Interleukin-4; D012313:RNA; D007371:Interferon-gamma